A prospective study on the effects of glucosamine hydrochloride and chondroitin sulfate combination on systemic inflammation markers in patients with knee osteoarthritis (report 1)

Objective: to assess the effect of a combination of glucosamine hydrochloride (GH) 500 mg and chondroitin sulfate (CS) 500 mg (Artra®) on systemic inflammation markers in patients with knee osteoarthritis (KOA).
Material and methods. The study included 70 patients with a confirmed diagnosis of KOA stage II–III and walking pain ≥4 points on a numerical rating scale (NRS). Study duration was 3 months. All patients received Artra® and, if necessary, topical nonsteroidal anti-inflammatory drugs (NSAIDs). Treatment efficacy was evaluated by changes in pain according to NRS, the WOMAC index, and patient global assessment of health status (PGA) using a visual analogue scale (VAS). C-reactive protein (CRP) levels were measured during visits 1 and 3 in all patients; 40 patients also had their serum levels of 17 cytokines, chemokines, and growth factors assessed.
Results and discussion. After 3 months of treatment, there was a rapid and significant decrease in pain according to NRS (from 5 [5; 6] to 3 [2; 4] points), pain on WOMAC (from 9 [7; 11] to 5 [3; 8] points), stiffness on WOMAC (from 4 [3; 5] to 3 [1; 4] points), improvement in physical function on WOMAC (from 36 [24; 41] to 23.5 [12; 32] points), and PGA (from 50 [50; 70] to 65 [58; 75] mm), p<0.0001 for all comparisons. A decrease was also observed in the number of patients with clinically apparent synovitis (p=0.04) and limited range of motion in the knee joint (p<0.0001). A significant advantage of the GH and CS combination is its impact on inflammatory markers – in particular, a reduction in tumor necrosis factor alpha (TNFα) levels (p=0.04).
Conclusion. In patients with KOA, Artra® demonstrated a rapid symptomatic effect, which continued to increase over the 3-month observation period. Our study confirmed the more subtle molecular mechanisms behind the beneficial effects of the GH and CS combination through suppression of inflammatory mediator production, particularly TNFα. These findings suggest a systemic effect of the drug, making it particularly promising for treating patients with comorbidities.

1. GBD 2021 Osteoarthritis Collaborators. Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023 Aug 21;5(9):e508-e522. doi: 10.1016/S2665-9913(23)00163-7.

2. Li B, Yang Z, Li Y, et al. Exploration beyond osteoarthritis: the association and mechanism of its related comorbidities. Front Endocrinol (Lausanne). 2024 Apr 19:15: 1352671. doi: 10.3389/fendo.2024.1352671.

3. Herrero-Beaumont G, Castro-Dominguez F, Migliore A, et al. Systemic osteoarthritis: the difficulty of categorically naming a continuous condition. Aging Clin Exp Res. 2024 Feb 20;36(1):45. doi: 10.1007/s40520-024-02714-w.

4. Lila AM, Taskina EA, Alekseeva LI, Kashevarova NG. Symptomatic delayed-acting drugs (SYSADOA): new applications. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2022;16(2):99-106. (In Russ.). doi: 10.14412/1996-7012-2022-2-99-106.

5. Taskina EA, Alekseeva LI, Kashevarova NG, et al. Multimorbidity in osteoarthritis. Nauchno-Prakticheskaya Revmatologia. 2022; 60(3):306–313. (In Russ.).

6. Brito R, Costa D, Dias C, et al. Chondroitin Sulfate Supplements for Osteoarthritis: A Critical Review. Cureus. 2023 Jun 9;15(6): e40192. doi: 10.7759/cureus.40192. eCollection 2023 Jun.

7. Henrotin Y, Lambert C, Richette P. Importance of synovitis in osteoarthritis: evidence for the use of glycosaminoglycans against synovial inflammation. Semin Arthritis Rheum. 2014 Apr;43(5):579-87. doi: 10.1016/j.semarthrit.2013.10.005. Epub 2013 Oct 18.

8. Alexeeeva LI, Chichasova NV, Benevolenskaya LI, et al. Perspectives of combined chondroprotective therapy of osteoarthritis. Results of an open randomized study of Artra preparation in patiets with gonarthrosis. Nauchno-Prakticheskaya Revmatologia. 2004;42(4):77-79. (In Russ.).

9. Alekseeva LI, Chichasova NV, Mendel OI. Rational choice of basic therapy for osteoarthritis. Results of an open randomized multicenter trial of ARTRA® in Russia. Russkii meditsinskii zhurnal. 2005;13(24):1637-1640. (In Russ.).

10. Men'shikova LV, Khramtsova NA, Men'shikov ML. Use of the medication ARTRA in women with knee osteoarthrosis. Sovremennye problemy revmatologii. 2005;(2):192-198. (In Russ.).

11. Svetlova MS. The effectiveness of the drug "ARTRA" in the treatment of osteoarthritis (OA). Nauchno-prakticheskaya revmatologiya. 2006;44(2):109. (In Russ.).

12. Aleksenko EY, Govorin AV. Changes in the parameters of blood lipids and cytokines in patients with primary osteoarthritis during treatment with ARTRA. Nauchno-Prakticheskaya Revmatologia. 2011;49(3):37-40. (In Russ.).

13. Naumov AV, Vertkin AL, Mendel OI, et al. How to improve the safety and effectiveness of "antiarthrosis" therapy in patients with somatic pathology. Russkii meditsinskii zhurnal. 2007;(26):2012. (In Russ.).

14. Rodionova SS, Es'kin NA, Matveeva NYu, Morozova NS. Rational choice of treatment for the initial stages of gonarthrosis in patients suffering from systemic osteoporosis. Vestnik travmatologii i ortopedii im. N.N. Priorova. 2014;(2):52-56. (In Russ.).

15. Rodionova SS, Es'kin NA. The combination of chondroitin sulfate and glucosamine (ARTRA) for pain relief and to reduce the consumption of NSAIDs in patients with I–II stages of osteoarthritis of the knee. Khirurgiya. Zhurnal im. N.I. Pirogova. 2016;(1):67-72. (In Russ.).

16. Shaltabaeva AB, Sheval'e AN, Shaimerdenova AB. The effectiveness of the drug "ARTRA" in the treatment of osteoarthritis of the knee joints in outpatient settings. Collection of articles of the XI International Scientific and Practical Competition. Penza: Nauka i prosveshchenie; 2017. P. 324-7.

17. Alekseeva LI, Lila AM, Sharapova EP, et al. Multicenter prospective observational study on the use of ARTHRA® MSM FORTE and ARTHRA® in patients with osteoarthritis of the knee and/or hip joints and/or with lower back pain (preliminary results). Trudnyi patsient. 2018;16(6):34-41. (In Russ.).

18. Aleksenko EYu, Govorin AV. Efficacy and safety of long-term use of a combined chondroprotector for the treatment of osteoarthritis of the knee joints: an open prospective randomized trial. Farmateka. 2018;(S2):26-33. (In Russ.).

19. Mukherjee A, Das B. The role of inflammatory mediators and matrix metalloproteinases (MMPs) in the progression of osteoarthritis. Biomater Biosyst. 2024 Feb 21:13: 100090. doi: 10.1016/j.bbiosy.2024.100090. eCollection 2024 Mar.

20. Molnar V, Matisic V, Kodvanj I, et al. Cytokines and Chemokines Involved in Osteoarthritis Pathogenesis. Int J Mol Sci. 2021 Aug 26;22(17):9208. doi: 10.3390/ijms22179208.